Pharmacogenetic guidance for antiplatelet treatment

Young Hoon Jeong; Kevin P. Bliden; Yongwhi Park; Udaya S. Tantry; Paul A. Gurbel

doi:10.1016/S0140-6736(12)61398-1

Pharmacogenetic guidance for antiplatelet treatment

Young Hoon Jeong, Kevin P. Bliden, Yongwhi Park, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	725
Number of pages	1
Journal	The Lancet
Volume	380
Issue number	9843
DOIs	https://doi.org/10.1016/S0140-6736(12)61398-1
State	Published - Aug 2012
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(12)61398-1

Cite this

@article{8c607b29c1eb4b51b65f04daeb09c7aa,

title = "Pharmacogenetic guidance for antiplatelet treatment",

author = "Jeong, {Young Hoon} and Bliden, {Kevin P.} and Yongwhi Park and Tantry, {Udaya S.} and Gurbel, {Paul A.}",

note = "Funding Information: Y-HJ has received honoraria for lectures from Sanofi-Aventis, Daiichi Sankyo, Eli Lilly, Nanosphere, and Otsuka; and research grants or support from Dong-A Pharmaceutical, Boehringer Ingelheim, Otsuka, Accumetrics, and Multiplate. PAG has received research grants, honoraria, and consultant fees from AstraZeneca, Merck, Medtronic, Lilly/Daiichi Sankyo, Sanofi Aventis/Bristol Myers, Novartis, Boston Scientific, Bayer, Accumetrics, Boehringer Ingelheim, and Johnson and Johnson. The other authors declare that they have no conflicts of interest.",

year = "2012",

month = aug,

doi = "10.1016/S0140-6736(12)61398-1",

language = "English (US)",

volume = "380",

pages = "725",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9843",

}

TY - JOUR

T1 - Pharmacogenetic guidance for antiplatelet treatment

AU - Jeong, Young Hoon

AU - Bliden, Kevin P.

AU - Park, Yongwhi

AU - Tantry, Udaya S.

AU - Gurbel, Paul A.

N1 - Funding Information: Y-HJ has received honoraria for lectures from Sanofi-Aventis, Daiichi Sankyo, Eli Lilly, Nanosphere, and Otsuka; and research grants or support from Dong-A Pharmaceutical, Boehringer Ingelheim, Otsuka, Accumetrics, and Multiplate. PAG has received research grants, honoraria, and consultant fees from AstraZeneca, Merck, Medtronic, Lilly/Daiichi Sankyo, Sanofi Aventis/Bristol Myers, Novartis, Boston Scientific, Bayer, Accumetrics, Boehringer Ingelheim, and Johnson and Johnson. The other authors declare that they have no conflicts of interest.

PY - 2012/8

Y1 - 2012/8

UR - http://www.scopus.com/inward/record.url?scp=84865383974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865383974&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(12)61398-1

DO - 10.1016/S0140-6736(12)61398-1

M3 - Letter

C2 - 22920743

AN - SCOPUS:84865383974

SN - 0140-6736

VL - 380

SP - 725

JO - The Lancet

JF - The Lancet

IS - 9843

ER -

Pharmacogenetic guidance for antiplatelet treatment

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this